ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Olaratumab Biosimilar - Anti-PDGFR alpha Antibody - BSA and Azide free (A339004)

Recombinant human monoclonal antibody to PDGFR alpha for use as a research grade Olaratumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 7-10 business days.
Name
Olaratumab Biosimilar - Anti-PDGFR alpha Antibody - BSA and Azide free
Description
Recombinant human monoclonal antibody to PDGFR alpha for use as a research grade Olaratumab biosimilar.
Applications
ELISA, Flow Cytometry, Functional Studies, in vivo Research
Reactivity
Human
Host
Human
Clonality
Monoclonal
Isotype
IgG1
Conjugate

Unconjugated

Purity
The purity of this Biosimilar is >95%, as determined by SDS-PAGE.
Product Form
Liquid
Formulation
Supplied in 0.01M Phosphate Buffered Saline, pH 7.4.
Storage
Shipped at 4°C. Upon delivery store at 4°C for short-term use (1-2 weeks) or aliquot and store at -20°C for long-term use (up to 12 months).
Synonyms
Alpha platelet-derived growth factor receptor, Alpha-type platelet-derived growth factor receptor, CD140 antigen-like family member A, CD140a, CD140a antigen, PDGF-R-alpha, PDGFR-2, PDGFR-alpha, PDGFR2, PDGFRA, Platelet-derived growth factor alpha receptor, Platelet-derived growth factor receptor 2, Platelet-derived growth factor receptor alpha, RHEPDGFRA
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Olaratumab Biosimilar - Anti-PDGFR alpha Antibody - BSA and Azide free (A339004)? Please let us know so that we can list the citation on this page.

Alternative products to Olaratumab Biosimilar - Anti-PDGFR alpha Antibody - BSA and Azide free (A339004)

Proteins predicted to interact with PDGFR alpha

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
99.9% Relevancy Score
99.9% Relevancy Score
99.9% Relevancy Score
99.9% Relevancy Score
99.5% Relevancy Score
99.5% Relevancy Score
99% Relevancy Score
98.9% Relevancy Score
98.8% Relevancy Score